Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria

J Infect Dis. 2003 Oct 15;188(8):1231-8. doi: 10.1086/378523. Epub 2003 Oct 10.

Abstract

Combination antimalarial therapy may delay the spread of drug resistance, but clinical data supporting this notion are limited. For 1 year, we studied Ugandan children who were treated for uncomplicated malaria with sulfadoxine-pyrimethamine (SP), SP + amodiaquine (AQ), or SP + artesunate (AS). We compared treatment responses and the prevalence of resistance-conferring mutations of new infections with those of recrudescent infections due to parasites that survived prior treatment. Recrudescent infections were associated with the selection of SP resistance-conferring mutations in all treatment groups, but responses to repeat therapy differed. Compared with initial treatments, treatment of recrudescent infections was associated with a higher rate of treatment failure (hazard ratio [HR], 2.44; P=.01), for the SP group, but with a lower rate of treatment failure (HR, 0.40; P=.08), for the SP + AS group. Treatment failure in the SP + AQ group was uncommon, limiting the analysis of recrudescent parasites. Our results suggest that the use of combination antimalarial therapy in Africa may slow the spread of drug-resistant malaria and prolong the therapeutic life span of available treatment regimens.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amodiaquine / administration & dosage
  • Amodiaquine / pharmacology
  • Amodiaquine / therapeutic use*
  • Animals
  • Antimalarials / administration & dosage
  • Antimalarials / pharmacology
  • Antimalarials / therapeutic use*
  • Artemisinins / administration & dosage
  • Artemisinins / pharmacology
  • Artemisinins / therapeutic use*
  • Artesunate
  • Child, Preschool
  • Dihydropteroate Synthase / genetics
  • Drug Administration Schedule
  • Drug Combinations
  • Drug Resistance* / genetics
  • Drug Therapy, Combination
  • Humans
  • Infant
  • Malaria, Falciparum / drug therapy*
  • Malaria, Falciparum / parasitology
  • Mutation
  • Plasmodium falciparum / drug effects
  • Pyrimethamine / administration & dosage
  • Pyrimethamine / pharmacology
  • Pyrimethamine / therapeutic use*
  • Sesquiterpenes / administration & dosage
  • Sesquiterpenes / pharmacology
  • Sesquiterpenes / therapeutic use*
  • Sulfadoxine / administration & dosage
  • Sulfadoxine / pharmacology
  • Sulfadoxine / therapeutic use*
  • Tetrahydrofolate Dehydrogenase / genetics
  • Treatment Failure
  • Treatment Outcome

Substances

  • Antimalarials
  • Artemisinins
  • Drug Combinations
  • Sesquiterpenes
  • Amodiaquine
  • fanasil, pyrimethamine drug combination
  • Artesunate
  • Sulfadoxine
  • Tetrahydrofolate Dehydrogenase
  • Dihydropteroate Synthase
  • Pyrimethamine